Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

44.72
-0.2100-0.47%
Post-market: 44.750.0300+0.07%19:56 EDT
Volume:7.81M
Turnover:347.89M
Market Cap:3.35B
PE:-12.84
High:45.01
Open:44.85
Low:44.19
Close:44.93
Loading ...

SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder

MT Newswires Live
·
12 Feb

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Springworks Therapeutics (SWTX)

TIPRANKS
·
12 Feb

Update: SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Soars 7% After-Hours on FDA Approval for Rare Disease Drug, Merck Acquisition Talks

Stock Track
·
12 Feb

BRIEF-Springworks Therapeutics Announces FDA Approval Of Gomekli (Mirdametinib) For Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
·
12 Feb

SpringWorks Therapeutics confirms FDA approval of Gomekli

TIPRANKS
·
12 Feb

SpringWorks Therapeutics Announces FDA Approval of Gomekli™ (Mirdametinib) for the Treatment of Adult and Pediatric Patients With Nf1-Pn

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Plunges 5.98% After Hours on Profitability Concerns Over Potential Merck Acquisition

Stock Track
·
12 Feb

US FDA approves SpringWorks' genetic disorder drug

Reuters
·
12 Feb

BRIEF-FDA Approved Mirdametinib, For Adult & Pediatric Patients 2 Years Of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable To Complete Resection

Reuters
·
12 Feb

US FDA approves Springworks' genetic disorder drug

Reuters
·
12 Feb

FDA approves SpringWorks’ mirdametinib for adult and pediatric NF1 patients

TIPRANKS
·
12 Feb

FDA: Approved Mirdametinib, for Adult & Pediatric Patients 2 Years of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable to Complete Resection

THOMSON REUTERS
·
12 Feb

Stock Track | SpringWorks Therapeutics Plummets 5.04% on Profitability Concerns Over Potential Merck Acquisition

Stock Track
·
11 Feb

Deals of the day-Mergers and acquisitions

Reuters
·
11 Feb

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Dow Jones
·
11 Feb

Springworks Therapeutics (SWTX) Gets a Buy from Barclays

TIPRANKS
·
11 Feb

Germany's Merck in Talks to Buy SpringWorks Therapeutics

Dow Jones
·
11 Feb

Merck KGaA Confirms Discussions With Springworks Therapeutics On Potential Acquisition

Reuters
·
11 Feb

Merck KGaA confirms ‘advanced’ talks to acquire SpringWorks

TIPRANKS
·
11 Feb